Al Hammadi Reports SAR 56.24M Net Profit in Three Months 2026
ALHAMMADI 4007.SA | 0.00 |
On 2026-05-10 08:09:47 (Saudi Time), Al Hammadi Holding announced its Interim financial results for the three months ended on March 31, 2026.
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 319.09 | 301.88 | 5.7 | 339.5 | -6.011 |
| Gross Profit (Loss) | 101.09 | 96.51 | 4.745 | 90.5 | 11.701 |
| Operational Profit (Loss) | 52.55 | 76.73 | -31.513 | 59.2 | -11.233 |
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 56.24 | 73.93 | -23.928 | 54.08 | 3.994 |
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 52.76 | 75.24 | -29.877 | 52.84 | -0.151 |
| All figures are in (Millions) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Total Shareholders Equity (after Deducting Minority Equity) | 2,025.92 | 1,980.5 | 2.293 |
| Profit (Loss) per Share | 0.35 | 0.46 | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Millions) Saudi Arabia, Riyals | |||
Year-on-Year Performance Drivers
Sales increased 5.7% YoY to SAR 319.09 million, driven primarily by 17.7% growth in the Pharmaceutical Products segment and 2.6% growth in Medical Services. However, net profit declined 23.928% YoY to SAR 56.24 million despite higher revenues, mainly due to a 41.5% surge in general, administrative, selling and marketing expenses related to the Al Hammadi Hospitals Group rebranding campaign, and a significant increase in expected credit loss provisions of SAR 17.31 million compared to a reversal of SAR 0.33 million in the prior year quarter due to delayed payments from major clients.
Quarter-on-Quarter Performance Drivers
QoQ revenue declined 6.011% to 319.09 million SAR due to seasonal factors during Ramadan and Eid Al-Fitr, which temporarily impacted operational levels in Medical and Pharmaceutical sectors. Net profit increased 3.994% to 56.24 million SAR, driven by improved gross margin from 26.7% to 31.7% through enhanced cost management and operational efficiency. Additionally, the company's share of net profits from associates surged 174.8% to 14.55 million SAR, contributing significantly to the overall profit growth.
Other Items
The auditors issued an unmodified conclusion with no additional comments, disclaimers, or adverse opinions noted. No material uncertainties or significant risks were highlighted in the audit report. The company reported earnings per share of SAR 0.35 for the current quarter compared to SAR 0.46 in the same quarter of the previous year. Total shareholders' equity increased 2.293% to SAR 2,025.92 million from SAR 1,980.5 million in the prior year period.
Original announcement:
https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=95116&anCat=1&cs=4007&locale=arImportant Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.